Drug Trial Radar · NCT02155660
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Last checked: Nov 20, 2026Latest source record: Jun 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,255
Actual
Start
Jun 25, 2014
Primary completion
Apr 9, 2018
Study completion Apr 9, 2018
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- MedImmune LLC
- First posted
- Jun 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.
Conditions
- Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm ADrug
Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Benralizumab Arm BDrug
Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Benralizumab Arm CDrug
Benralizumab subcutaneously on study week 0 until study week 48 inclusive
PlaceboDrug
Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uLTime frame: Immediately following the first IP dose through week 56
Locations
356 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Gulf Shores, Alabama
Research Site
Montgomery, Alabama
Research Site
Flagstaff, Arizona
Research Site
Phoenix, Arizona
Research Site
Anaheim, California
Research Site
Arcadia, California
Research Site
Bakersfield, California
Research Site
Fresno, California
Research Site
Fullerton, California
Research Site
Hawaiian Gardens, California
Research Site
Huntington Beach, California
Research Site
Los Angeles, California
Research Site
Northridge, California
Research Site
Palmdale, California
Research Site
Peninsula, California
Research Site
Placentia, California
Research Site
Rolling Hills Estates, California
Research Site
Westminster, California
Research Site
Centennial, Colorado
Research Site
Colorado Springs, Colorado
Research Site
Denver, Colorado
Research Site
Chiefland, Florida
Research Site
Clearwater, Florida
Research Site
Clearwater, Florida
Research Site
Coconut Creek, Florida
Research Site
Coral Gables, Florida
Research Site
Daytona Beach, Florida
Research Site
DeBary, Florida
Research Site
DeLand, Florida
Research Site
Doral, Florida
Research Site
Edgewater, Florida
Research Site
Fort Lauderdale, Florida
Research Site
Hialeah, Florida
Research Site
Hialeah, Florida
Research Site
Hialeah, Florida
Research Site
Homestead, Florida
Research Site
Jacksonville, Florida
Research Site
Kissimmee, Florida
Research Site
Miami, Florida
Showing 40 of 356 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.